Roche
Roche Q3 Pharmaceutical Revenues Grow 5 Percent Helped by Precision Cancer Drugs
HER2-targeted breast cancer drugs and the immunotherapy Tecentriq were among the top-selling therapies during the quarter.
FDA Approves Genentech's Tecentriq as Adjuvant Treatment for PD-L1-Expressing NSCLC
The agency also approved the Ventana PD-L1 Assay from Roche's Ventana Medical Systems as a companion diagnostic device.
Real-World Data from OneOncology, Roche Shed Light on NSCLC NGS Trends in Community Practices
Premium
The percentage of NSCLC patients undergoing biomarker testing has increased in recent years, but turnaround time and socioeconomic disparities need addressing.
UK's NICE Recommends Roche's Tecentriq for First-Line PD-L1-Positive Bladder Cancer
The committee recommends the agent be available to patients whose cancers express PD-L1 in at least 5 percent of cells and for whom platinum chemo isn't an option.
In Brief This Week: Zai Lab, Roche, Realm IDx
News items for the week of Sept. 13, 2021.